Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Gastric Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 29 articles:
HTML format



Single Articles


    March 2024
  1. WEI Q, Yang T, Zhu J, Zhang Z, et al
    Spatiotemporal Quantification of HER2-targeting Antibody-Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration.
    Clin Cancer Res. 2024;30:984-997.
    PubMed     Abstract available


    February 2024
  2. CAO L, Zhou J, Zhang J, Wu S, et al
    Editor's Note: Cyclin-Dependent Kinase 5 Decreases in Gastric Cancer and its Nuclear Accumulation Suppresses Gastric Tumorigenesis.
    Clin Cancer Res. 2024;30:918.
    PubMed    


    January 2024
  3. KAWAZOE A, Yamamoto N, Sugimoto N, Kawakami H, et al
    Phase 2 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort.
    Clin Cancer Res. 2024 Jan 31. doi: 10.1158/1078-0432.CCR-23-1768.
    PubMed     Abstract available


    October 2023
  4. KLEMPNER SJ, Lee KW, Shitara K, Metges JP, et al
    ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
    Clin Cancer Res. 2023;29:3882-3891.
    PubMed     Abstract available


    July 2023
  5. MARON SB, Chatila W, Walch H, Chou JF, et al
    Determinants of survival in HER2+ metastatic esophagogastric cancer.
    Clin Cancer Res. 2023 Jul 5:CCR-22-3769. doi: 10.1158/1078-0432.CCR-22-3769.
    PubMed     Abstract available


    February 2023
  6. SHITARA K, Hirao M, Iwasa S, Oshima T, et al
    Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF): Results From the Advanced Gastric Cancer Expansion Cohort.
    Clin Cancer Res. 2023 Feb 2:CCR-22-3027. doi: 10.1158/1078-0432.CCR-22-3027.
    PubMed     Abstract available


    December 2022
  7. PARK S, Karalis JD, Hong C, Clemenceau JR, et al
    ACTA2 expression predicts survival and is associated with response to immune checkpoint inhibitors in gastric cancer.
    Clin Cancer Res. 2022 Dec 12:CCR-22-1897. doi: 10.1158/1078-0432.CCR-22-1897.
    PubMed     Abstract available


    November 2022
  8. PIETRANTONIO F, Manca P, Bellomo SE, Corso S, et al
    HER2 copy number and resistance mechanisms in patients with HER2-positive advanced gastric cancer receiving initial trastuzumab-based therapy in JACOB trial.
    Clin Cancer Res. 2022 Nov 22:CCR-22-2533. doi: 10.1158/1078-0432.CCR-22-2533.
    PubMed     Abstract available


    October 2022
  9. PENG K, Zhang F, Wang Y, Sahgal P, et al
    Development of combination strategies for Focal Adhesion Kinase inhibition in Diffuse Gastric Cancer.
    Clin Cancer Res. 2022 Oct 24. pii: 710014. doi: 10.1158/1078-0432.CCR-22-1609.
    PubMed     Abstract available


    June 2022
  10. YUKAMI H, Kawazoe A, Lin YT, Koyama S, et al
    Updated efficacy outcomes of anti-PD-1 antibodies plus multikinase inhibitors for advanced gastric cancer patients with or without liver metastases in clinical trials.
    Clin Cancer Res. 2022 Jun 9. pii: 704845. doi: 10.1158/1078-0432.CCR-22-0630.
    PubMed     Abstract available


  11. LEE KW, Van Cutsem E, Bang YJ, Fuchs CS, et al
    Association of Tumor Mutational Burden with Efficacy of Pembrolizumab{plus minus}Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study.
    Clin Cancer Res. 2022 Jun 3. pii: 699374. doi: 10.1158/1078-0432.CCR-22-0121.
    PubMed     Abstract available


    April 2022
  12. WANG J, Kunzke T, Prade VM, Shen J, et al
    Spatial metabolomics identifies distinct tumor-specific subtypes in gastric cancer patients.
    Clin Cancer Res. 2022 Apr 8. pii: 694328. doi: 10.1158/1078-0432.CCR-21-4383.
    PubMed     Abstract available


    September 2021
  13. HUANG H, Brekken RA
    Location matters: Profiling diffuse type gastric cancer at the single cell level.
    Clin Cancer Res. 2021 Sep 23. pii: 1078-0432.CCR-21-2935.
    PubMed     Abstract available


    August 2021
  14. JEONG HY, Ham IH, Lee SH, Ryu D, et al
    Spatially distinct reprogramming of the tumor microenvironment based on tumor invasion in diffuse-type gastric cancers.
    Clin Cancer Res. 2021 Aug 12. pii: 1078-0432.CCR-21-0792.
    PubMed     Abstract available


  15. JOGO T, Nakamura Y, Shitara K, Bando H, et al
    Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer.
    Clin Cancer Res. 2021 Aug 10. pii: 1078-0432.CCR-21-1414.
    PubMed     Abstract available


    July 2021
  16. MOUTAFI M, Rimm DL
    Putting the Microenvironment into the Immunotherapy Companion Diagnostic.
    Clin Cancer Res. 2021;27:3812-3814.
    PubMed     Abstract available


  17. DE CLERCQ NC, van den Ende T, Prodan A, Hemke R, et al
    Fecal Microbiota Transplantation from Overweight or Obese Donors in Cachectic Patients with Advanced Gastroesophageal Cancer: A Randomized, Double-blind, Placebo-Controlled, Phase II Study.
    Clin Cancer Res. 2021;27:3784-3792.
    PubMed     Abstract available


    June 2021
  18. OPENSHAW MR, Pinato DJ, Valeri N
    Back from the Brink: EGFR Inhibition in Gastroesophageal Cancer.
    Clin Cancer Res. 2021;27:2964-2966.
    PubMed     Abstract available


  19. PENG Z, Wei J, Wang F, Ying J, et al
    Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
    Clin Cancer Res. 2021;27:3069-3078.
    PubMed     Abstract available


  20. CORSO S, Pietrantonio F, Apicella M, Migliore C, et al
    Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas.
    Clin Cancer Res. 2021;27:3126-3140.
    PubMed     Abstract available


    April 2021
  21. WIEDERMANN U, Garner-Spitzer E, Chao Y, Maglakelidze M, et al
    Clinical and immunologic responses to a B-cell epitope vaccine in HER2/neu overexpressing advanced gastric cancer patients - results from Phase 1b trial IMU.ACS.001.
    Clin Cancer Res. 2021 Apr 20. pii: 1078-0432.CCR-20-3742.
    PubMed     Abstract available


  22. CATENACCI DVT
    A PERFECT biomarker-focused study of neoadjuvant IO for esophagogastric cancer.
    Clin Cancer Res. 2021 Apr 6. pii: 1078-0432.CCR-21-0324.
    PubMed     Abstract available


  23. WAINBERG ZA, Fuchs CS, Tabernero J, Shitara K, et al
    Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score >/=10.
    Clin Cancer Res. 2021;27:1923-1931.
    PubMed     Abstract available


    March 2021
  24. LEI M, Siemers NO, Pandya D, Chang H, et al
    Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab{plus minus}Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer.
    Clin Cancer Res. 2021 Mar 29. pii: 1078-0432.CCR-20-2790.
    PubMed     Abstract available


    February 2021
  25. LEE IS, Lee H, Hur H, Kanda M, et al
    Transcriptomic Profiling Identifies A Risk Stratification Signature for Predicting Peritoneal Recurrence and Micrometastasis in Gastric Cancer.
    Clin Cancer Res. 2021 Feb 8. pii: 1078-0432.CCR-20-3835.
    PubMed     Abstract available


    December 2020
  26. NAKAJIMA TE, Kadowaki S, Minashi K, Nishina T, et al
    Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer.
    Clin Cancer Res. 2020 Dec 1. pii: 1078-0432.CCR-20-3559.
    PubMed     Abstract available


    November 2020
  27. PARK J, Jang BG, Kim YW, Park H, et al
    A prospective validation and observer performance study of a deep learning algorithm for pathologic diagnosis of gastric tumors in endoscopic biopsies.
    Clin Cancer Res. 2020 Nov 10. pii: 1078-0432.CCR-20-3159.
    PubMed     Abstract available


    June 2020
  28. XU J, Bai Y, Xu N, Li E, et al
    Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
    Clin Cancer Res. 2020 Jun 19. pii: 1078-0432.CCR-19-3561.
    PubMed     Abstract available


    February 2020
  29. KELLY RJ, Lee J, Bang YJ, Almhanna K, et al
    Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.
    Clin Cancer Res. 2020;26:846-854.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gastric Cancer is free of charge.